May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Incidence of Systemic Adverse Events in Patients Treated With Intravitreal Bevacizumab (Avastin)
Author Affiliations & Notes
  • M. Weiss
    Ophthalmology, Robert Wood Johnson Med School, New Brunswick, New Jersey
  • D. B. Roth
    Ophthalmology, Robert Wood Johnson Med School, New Brunswick, New Jersey
  • J. L. Prenner
    Ophthalmology, Robert Wood Johnson Med School, New Brunswick, New Jersey
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4939. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Weiss, D. B. Roth, J. L. Prenner; The Incidence of Systemic Adverse Events in Patients Treated With Intravitreal Bevacizumab (Avastin). Invest. Ophthalmol. Vis. Sci. 2007;48(13):4939.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: The use of off-label intravitreal bevacizumab (Avastin) has been reported for treatment of exudative macular degeneration, diabetic retinopathy, and retinal venous occlusive disease. Although the systemic side effects of intravenous bevacizumab are well documented, less is known regarding the systemic adverse events in patients receiving intravitreal bevacizumab. We report the incidence of systemic adverse events in patients treated with intravitreal bevacizumab.

Methods:: A retrospective, consecutive chart review of all patients receiving intravitreal bevacizumab from August 1, 2005 until July 1, 2006 in a university affiliated group retina practice was performed. Report of any change in medical history was noted. Physicians were queried as to the identification of any patient experiencing uncontrolled systemic hypertension, gastrointestinal bleeding, cerebrovascular accident, or other cardiovascular decompensation.

Results:: 492 patients receiving 1010 injections of intravitreal bevacizumab were identified. Three patients (0.6%) experienced a severe elevation in their blood pressure, one patient (0.2%) developed a cerebrovascular accident, one patient (0.2%) developed a myocardial infarction, one patient (0.2%) developed a severe gastrointestinal bleed leading to hypotension, myocardial ischemia and death, and one patient (0.2%) developed ischemic colitis with resultant gastrointestinal bleeding and anemia. Data from formal questionnaires of patients directed at systemic medical history in order to obtain more complete information will be presented.

Conclusions:: Intravitreal bevacizumab seems to have a low incidence of systemic adverse events, however, under reporting of systemic adverse events based on ophthalmic chart review is probable. Outside of an organized clinical trial, systemic medical information is often overlooked. Direct questioning of patients is necessary in order to obtain more complete data.

Keywords: age-related macular degeneration • drug toxicity/drug effects • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×